MED12 Related Disorders FTNW
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Reframing Psychiatry for Precision Medicine
Reframing Psychiatry for Precision Medicine Elizabeth B Torres 1,2,3* 1 Rutgers University Department of Psychology; [email protected] 2 Rutgers University Center for Cognitive Science (RUCCS) 3 Rutgers University Computer Science, Center for Biomedicine Imaging and Modelling (CBIM) * Correspondence: [email protected]; Tel.: (011) +858-445-8909 (E.B.T) Supplementary Material Sample Psychological criteria that sidelines sensory motor issues in autism: The ADOS-2 manual [1, 2], under the “Guidelines for Selecting a Module” section states (emphasis added): “Note that the ADOS-2 was developed for and standardized using populations of children and adults without significant sensory and motor impairments. Standardized use of any ADOS-2 module presumes that the individual can walk independently and is free of visual or hearing impairments that could potentially interfere with use of the materials or participation in specific tasks.” Sample Psychiatric criteria from the DSM-5 [3] that does not include sensory-motor issues: A. Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history (examples are illustrative, not exhaustive, see text): 1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions. 2. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication. -
Methylation Status of Vitamin D Receptor Gene Promoter in Adrenocortical Carcinoma
UNIVERSITÀ DEGLI STUDI DI PADOVA DEPARTMENT OF CARDIAC, THORACIC AND VASCULAR SCIENCES Ph.D Course Medical Clinical and Experimental Sciences Curriculum Clinical Methodology, Endocrinological, Diabetological and Nephrological Sciences XXIX° SERIES METHYLATION STATUS OF VITAMIN D RECEPTOR GENE PROMOTER IN ADRENOCORTICAL CARCINOMA Coordinator: Ch.mo Prof. Annalisa Angelini Supervisor: Ch.mo Prof. Francesco Fallo Ph.D Student: Andrea Rebellato TABLE OF CONTENTS SUMMARY 3 INTRODUCTION 4 PART 1: ADRENOCORTICAL CARCINOMA 4 1.1 EPIDEMIOLOGY 4 1.2 GENETIC PREDISPOSITION 4 1.3 CLINICAL PRESENTATION 6 1.4 DIAGNOSTIC WORK-UP 7 1.4.1 Biochemistry 7 1.4.2 Imaging 9 1.5 STAGING 10 1.6 PATHOLOGY 11 1.7 MOLECULAR PATHOLOGY 14 1.7.1 DNA content 15 1.7.2 Chromosomal aberrations 15 1.7.3 Differential gene expression 16 1.7.4 DNA methylation 17 1.7.5 microRNAs 18 1.7.6 Gene mutations 19 1.8 PATHOPHYSIOLOGY OF MOLECULAR SIGNALLING 21 PATHWAYS 1.8.1 IGF-mTOR pathway 21 1.8.2 WNTsignalling pathway 22 1.8.3 Vascular endothelial growth factor 23 1.9 THERAPY 24 1.9.1 Surgery 24 1.9.2 Adjuvant Therapy 27 1.9.2.1 Mitotane 27 1.9.2.2 Cytotoxic chemotherapy 30 1.9.2.3 Targeted therapy 31 1.9.2.4 Therapy for hormone excess 31 1.9.2.5 Radiation therapy 32 1.9.2.6 Other local therapies 32 1.10 PROGNOSTIC FACTORS AND PREDICTIVE MARKERS 32 PART 2: VITAMIN D 35 2.1 VITAMIN D AND ITS BIOACTIVATION 35 2.2 THE VITAMIN D RECEPTOR 37 2.3 GENOMIC MECHANISM OF 1,25(OH)2D3-VDR COMPLEX 38 2.4 CLASSICAL ROLES OF VITAMIN D 40 2.4.1 Intestine 40 2.4.2 Kidney 41 2.4.3 Bone 41 2.5 PLEIOTROPIC -
The Advantage of Genome-Wide Microarrays Over Targeted Approaches
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/70828 Please be advised that this information was generated on 2021-09-24 and may be subject to change. COPY NUMBER VARIATION AND MENTAL RETARDATION opmaak koolen.indd 1 10-09-2008 10:11:31 Copy number variation and mental retardation The studies presented in this thesis were performed at the Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. The research was supported by a grant from the Netherlands Organization for Health Research and Development (ZonMw). Publication of this thesis was financially supported by the Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. ISBN/EAN 978-90-6464-290-6 © 2008 D.A. Koolen All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, by print or otherwise, without permission in writing from the author. Cover photo: Printed by: Ponsen & Looijen B.V., Wageningen opmaak koolen.indd 2 10-09-2008 10:11:31 Copy number variation and mental retardation Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen Proefschrift ter verkrijging van de graad doctor aan de Radboud Universiteit Nijmegen op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann, volgens besluit van het College van Decanen in het openbaar te verdedigen op donderdag 6 november 2008 om 15.30 uur precies door David Aljosja Koolen geboren op 22 juni 1976 te ‘s-Gravenhage opmaak koolen.indd 3 10-09-2008 10:11:32 Promotor: Prof. -
Evidence for Differential Alternative Splicing in Blood of Young Boys With
Stamova et al. Molecular Autism 2013, 4:30 http://www.molecularautism.com/content/4/1/30 RESEARCH Open Access Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders Boryana S Stamova1,2,5*, Yingfang Tian1,2,4, Christine W Nordahl1,3, Mark D Shen1,3, Sally Rogers1,3, David G Amaral1,3 and Frank R Sharp1,2 Abstract Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups related to cerebral volume. Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20). Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS, LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling. -
Genes in Eyecare Geneseyedoc 3 W.M
Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease. -
The Role of Gli3 in Inflammation
University of New Hampshire University of New Hampshire Scholars' Repository Doctoral Dissertations Student Scholarship Winter 2020 THE ROLE OF GLI3 IN INFLAMMATION Stephan Josef Matissek University of New Hampshire, Durham Follow this and additional works at: https://scholars.unh.edu/dissertation Recommended Citation Matissek, Stephan Josef, "THE ROLE OF GLI3 IN INFLAMMATION" (2020). Doctoral Dissertations. 2552. https://scholars.unh.edu/dissertation/2552 This Dissertation is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of University of New Hampshire Scholars' Repository. For more information, please contact [email protected]. THE ROLE OF GLI3 IN INFLAMMATION BY STEPHAN JOSEF MATISSEK B.S. in Pharmaceutical Biotechnology, Biberach University of Applied Sciences, Germany, 2014 DISSERTATION Submitted to the University of New Hampshire in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy In Biochemistry December 2020 This dissertation was examined and approved in partial fulfillment of the requirement for the degree of Doctor of Philosophy in Biochemistry by: Dissertation Director, Sherine F. Elsawa, Associate Professor Linda S. Yasui, Associate Professor, Northern Illinois University Paul Tsang, Professor Xuanmao Chen, Assistant Professor Don Wojchowski, Professor On October 14th, 2020 ii ACKNOWLEDGEMENTS First, I want to express my absolute gratitude to my advisor Dr. Sherine Elsawa. Without her help, incredible scientific knowledge and amazing guidance I would not have been able to achieve what I did. It was her encouragement and believe in me that made me overcome any scientific struggles and strengthened my self-esteem as a human being and as a scientist. -
COFACTORS of the P65- MEDIATOR COMPLEX
COFACTORS OF THE April 5 p65- MEDIATOR 2011 COMPLEX Honors Thesis Department of Chemistry and Biochemistry NICHOLAS University of Colorado at Boulder VICTOR Faculty Advisor: Dylan Taatjes, PhD PARSONNET Committee Members: Rob Knight, PhD; Robert Poyton, PhD Table of Contents Abstract ......................................................................................................................................................... 3 Introduction .................................................................................................................................................. 4 The Mediator Complex ............................................................................................................................. 6 The NF-κB Transcription Factor ................................................................................................................ 8 Hypothesis............................................................................................................................................... 10 Results ......................................................................................................................................................... 11 Discussion.................................................................................................................................................... 15 p65-only factors ...................................................................................................................................... 16 p65-enriched factors .............................................................................................................................. -
MED12 Mutations Link Intellectual Disability Syndromes with Dysregulated GLI3-Dependent Sonic Hedgehog Signaling
MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling Haiying Zhoua, Jason M. Spaethb, Nam Hee Kimb, Xuan Xub, Michael J. Friezc, Charles E. Schwartzc, and Thomas G. Boyerb,1 aDepartment of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, CA 94270; bDepartment of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229; and cGreenwood Genetic Center, Greenwood, SC 29646 Edited by Robert G. Roeder, The Rockefeller University, New York, NY, and approved September 13, 2012 (received for review December 20, 2011) Recurrent missense mutations in the RNA polymerase II Mediator divergent “tail” and “kinase” modules through which most activa- subunit MED12 are associated with X-linked intellectual disability tors and repressors target Mediator. The kinase module, compris- (XLID) and multiple congenital anomalies, including craniofacial, ing MED12, MED13, CDK8, and cyclin C, has been ascribed both musculoskeletal, and behavioral defects in humans with FG (or activating and repressing functions and exists in variable association Opitz-Kaveggia) and Lujan syndromes. However, the molecular with Mediator, implying that its regulatory role is restricted to a mechanism(s) underlying these phenotypes is poorly understood. subset of RNA polymerase II transcribed genes. Here we report that MED12 mutations R961W and N1007S causing Within the Mediator kinase module, MED12 is a critical trans- FG and Lujan syndromes, respectively, disrupt a Mediator-imposed ducer of regulatory information conveyed by signal-activated transcription factors linked to diverse developmental pathways, constraint on GLI3-dependent Sonic Hedgehog (SHH) signaling. We including the EGF, Notch, Wnt, and Hedgehog pathways (10–12). -
Prenatalscreen® Standard Technical Report
About PrenatalScreen® Prenatal Test PrenatalScreen® Prenatal Test is a genetic test that analyses fetal DNA, obtained from CVS or amniotic fluid following an invasive prenatal diagnosis, to screen for monogenic disorders in the fetus. Using the latest technologies, including Next Generation Sequencing (NGS), PrenatalScreen® Prenatal Test screen 744 genes for mutations causing over 1.000 severe genetic disorders in the fetus. PrenatalScreen® Prenatal Test allows for a comprehensive care and enables patients to make more informed reproductive decisions. Offering PrenatalScreen® Prenatal Test to a patient during pregnancy allows her to gain more knowledge about the potential to pass along a condition to the fetus. Aim of the test PrenatalScreen® Prenatal Test analyses DNA extracted from fetal cells in the amniotic fluid, collected through amniocentesis, or in the chorionic villi through villocentesis (CVS). The aim of this diagnositc test is to assess severe genetic diseases in the fetus, including the most common diseases in the European population. Genes listed in Table 1 were selected according to the incidence in the population of the disease caused by mutations in such genes, the severity of the clinical phenotype at birth and the importance of the related pathogenetic picture, in accordance with the indications of the American College of Medical Genetics (ACMG)(Grody et al., Genet Med 2013:15:482–483). PrenatalScreen®: Indication for testing PrenatalScreen® Prenatal Test is intended for patients who meet any of the following criteria: • Personal/familial anamnesis of hereditary genetic diseases; • For expectant mothers wishing to reduce the risk of a genetic diseases in the fetus; • For natural or in vitro fertilization (IVF)-derived pregnancies: • For couples using heterologus IVF procedures (egg/sperm donors). -
MED12 Gene Mediator Complex Subunit 12
MED12 gene mediator complex subunit 12 Normal Function The MED12 gene provides instructions for making a protein called mediator complex subunit 12. As its name suggests, this protein forms one part (subunit) of the mediator complex, which is a group of about 25 proteins that work together to regulate gene activity. The mediator complex physically links transcription factors, which are proteins that influence whether genes are turned on or off, with an enzyme called RNA polymerase II. Once transcription factors are attached, this enzyme initiates gene transcription, the process by which information stored in a gene's DNA is used to build proteins. Researchers believe that the MED12 protein is involved in many aspects of early development, including the development of nerve cells (neurons) in the brain. The MED12 protein is part of several chemical signaling pathways within cells. These pathways help direct a broad range of cellular activities, such as cell growth, cell movement (migration), and the process by which cells mature to carry out specific functions (differentiation). Health Conditions Related to Genetic Changes FG syndrome At least two mutations in the MED12 gene have been found to cause FG syndrome, which is characterized by intellectual disability, behavioral problems, and physical abnormalities including weak muscle tone (hypotonia) and obstruction of the anal opening (imperforate anus). The mutations that cause FG syndrome each change a single protein building block ( amino acid) in the MED12 protein. One mutation replaces the amino acid arginine with the amino acid tryptophan at protein position 961 (written as Arg961Trp or R961W). The other replaces the amino acid glycine with the amino acid glutamic acid at protein position 958 (written as Gly958Glu or G958E). -
Craniosynostosis Precision Panel Overview Indications Clinical Utility
Craniosynostosis Precision Panel Overview Craniosynostosis is defined as the premature fusion of one or more cranial sutures, often resulting in abnormal head shape. It is a developmental craniofacial anomaly resulting from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). As well, craniosynostosis can be simple when only one suture fuses prematurely or complex/compound when there is a premature fusion of multiple sutures. Complex craniosynostosis are usually associated with other body deformities. The main morbidity risk is the elevated intracranial pressure and subsequent brain damage. When left untreated, craniosynostosis can cause serious complications such as developmental delay, facial abnormality, sensory, respiratory and neurological dysfunction, eye anomalies and psychosocial disturbances. In approximately 85% of the cases, this disease is isolated and nonsyndromic. Syndromic craniosynostosis usually present with multiorgan complications. The Igenomix Craniosynostosis Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Craniosynostosis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion with or without the following manifestations: ‐ Microcephaly ‐ Scaphocephaly (elongated head) ‐ Anterior plagiocephaly ‐ Brachycephaly ‐ Torticollis ‐ Frontal bossing Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment in the form surgical procedures to relieve fused sutures, midface advancement, limited phase of orthodontic treatment and combined 1 orthodontics/orthognathic surgery treatment. -
The Role of Med12 in Tumorigenesis
Helsinki Graduate Program in Biotechnology and Molecular Biology (GPBM)/ Integrative Life Sciences (ILS) Doctoral Program THE ROLE OF MED12 IN TUMORIGENESIS Kati Kämpjärvi Department of Medical and Clinical Genetics, Medicum & Genome-Scale Biology Research Program, Research Programs Unit Faculty of Medicine University of Helsinki Helsinki, Finland Academic dissertation To be publicly discussed, with the permission of the Faculty of Medicine, University of Helsinki, in Haartman Institute, Lecture Hall 1, Haartmaninkatu 3, Helsinki, on the 18th of November 2016, at 12 noon. Helsinki 2016 Supervised by Docent Pia Vahteristo, Ph.D. Department of Medical and Clinical Genetics, Medicum Genome-Scale Biology Research Program, Research Programs Unit Faculty of Medicine University of Helsinki Helsinki, Finland Academy Professor Lauri A. Aaltonen, M.D., Ph.D. Department of Medical and Clinical Genetics, Medicum Genome-Scale Biology Research Program, Research Programs Unit Faculty of Medicine University of Helsinki Helsinki, Finland Reviewed by Docent Miina Ollikainen, Ph.D. Institute for Molecular Medicine Finland, FIMM Department of Public Health, Clinicum Faculty of Medicine University of Helsinki Helsinki, Finland Docent Katri Pylkäs, Ph.D. Laboratory of Cancer Genetics and Tumor Biology Biocenter Oulu Faculty of Medicine University of Oulu Oulu, Finland Official opponent Professor Anne Kallioniemi, M.D., Ph.D. BioMediTech University of Tampere Tampere, Finland ISBN 978-951-51-2643-6 (paperback) ISBN 978-951-51-2644-3 (PDF) htpp://ethesis.helsinki.fi